TABLE 2.

Sensitivity and Specificity of MRCP, With or Without Secretin Enhancement, for Detecting Ductal Abnormalities in Patients With Recurrent Acute Pancreatitis

Finding, Type of MRCP	Sensitivity, % (95% CI)	Specificity, % (95% CI)
Divisum
Non–secretin enhanced	57.1 (18.4–90.1)	95.7 (85.5–99.5)
Secretin enhanced	85.7 (42.1–99.6)	91.5 (79.6–97.6)
Main pancreatic duct dilation
Non–secretin enhanced	46.2 (19.2–74.9)	100 (91.4–100.0)
Secretin enhanced	85.7 (57.2–98.2)	97.5 (86.5–99.5)
Main pancreatic duct stricture
Non–secretin enhanced	66.7 (9.4–99.2)	96.1 (86.5–99.5)
Secretin enhanced	66.7 (9.4–99.2)	94.1 (83.8–98.8)
Side branch duct dilation
Non–secretin enhanced	21.4 (4.7–50.8)	95.0 (83.1–99.4)
Secretin enhanced	71.4 (41.9–91.6)	90.0 (76.3–97.2)
Any positive finding
Non–secretin enhanced	56.0 (34.9–75.6)	90.0 (72.6–97.8)
Secretin enhanced	76.0 (54.9–90.6)	88.1 (68.3–93.8)